For: | Ampuero J, Reddy KR, Romero-Gomez M. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. World J Gastroenterol 2016; 22(22): 5285-5292 [PMID: 27298572 DOI: 10.3748/wjg.v22.i22.5285] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v22/i22/5285.htm |
Number | Citing Articles |
1 |
Seyed Moayed Alavian, Behzad Hajarizadeh, Kamran Bagheri Lankarani, Heidar Sharafi, Nasser Ebrahimi Daryani, Shahin Merat, Minoo Mohraz, Masoud Mardani, Mohamad Reza Fattahi, Hossein Poustchi, Mehri Nikbin, Mahmood Nabavi, Peyman Adibi, Masood Ziaee, Bita Behnava, Mohammad Saeid Rezaee-Zavareh, Massimo Colombo, Hatef Massoumi, Abdul Rahman Bizri, Bijan Eghtesad, Majid Amiri, Ali Namvar, Khashayar Hesamizadeh, Reza Malekzadeh. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepatitis Monthly 2016; 16(8) doi: 10.5812/hepatmon.guideline
|
2 |
Seyed Moayed Alavian, Mohammad Saeid Rezaee-Zavareh. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepatitis Monthly 2016; 16(9) doi: 10.5812/hepatmon.41077
|
3 |
Maia Butsashvili, Lia Gvinjilia, George Kamkamidze, David Metreveli, Shorena Dvali, Tamar Rukhadze, Amiran Gamkrelidze, Muazzam Nasrullah, Shaun Shadaker, Juliette Morgan, Francisco Averhoff. High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia. BMC Research Notes 2020; 13(1) doi: 10.1186/s13104-020-05173-4
|
4 |
Jung-Ah Kang, Songwon Kim, Minji Park, Hyun-Jin Park, Jeong-Hyun Kim, Sanghyeok Park, Jeong-Ryul Hwang, Yong-Chul Kim, Yoon Jun Kim, Yuri Cho, Mi Sun Jin, Sung-Gyoo Park. Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly. Nature Communications 2019; 10(1) doi: 10.1038/s41467-019-10200-5
|
5 |
Juan Turnes, Raquel Domínguez-Hernández, Miguel Ángel Casado. Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. Gastroenterología y Hepatología (English Edition) 2017; 40(7): 433 doi: 10.1016/j.gastre.2017.07.008
|
6 |
Juan Turnes, Raquel Domínguez-Hernández, Miguel Ángel Casado. Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. Gastroenterología y Hepatología 2017; 40(7): 433 doi: 10.1016/j.gastrohep.2017.05.004
|
7 |
Javier Ampuero, Isabel Carmona, Francisca Sousa, Jose Miguel Rosales, Ángeles López-Garrido, Marta Casado, Banca Figueruela, Ana Aparicio, Raúl Andrade, María Fernanda Guerra-Veloz, Marta Maraver, Juan Manuel Pascasio, Matías Estévez, Manuel Romero-Gomez. A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. American Journal of Gastroenterology 2022; 117(1): 138 doi: 10.14309/ajg.0000000000001503
|
8 |
Ong The Due, Usa Chaikledkaew, Anne Julienne M. Genuino, Abhasnee Sobhonslidsuk, Ammarin Thakkinstian. Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6. BioMed Research International 2019; 2019: 1 doi: 10.1155/2019/2301291
|
9 |
Maximilian Salcher-Konrad, Mary Nguyen, Jelena Savović, Julian P. T. Higgins, Huseyin Naci. Treatment Effects in Randomized and Nonrandomized Studies of Pharmacological Interventions. JAMA Network Open 2024; 7(9): e2436230 doi: 10.1001/jamanetworkopen.2024.36230
|
10 |
Shaimaa Elshafie, Rupal Trivedi‐Kapoor, Mark Ebell. Safety and efficacy of sofosbuvir‐based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta‐analysis. Journal of Clinical Pharmacy and Therapeutics 2022; 47(8): 1149 doi: 10.1111/jcpt.13698
|